Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors
Authors
Keywords
-
Journal
AGING CELL
Volume 15, Issue 3, Pages 428-435
Publisher
Wiley
Online
2015-12-29
DOI
10.1111/acel.12445
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Growth hormone action predicts age-related white adipose tissue dysfunction and senescent cell burden in mice
- (2016) Michael B. Stout et al. Aging-US
- The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
- (2015) Yi Zhu et al. AGING CELL
- Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment
- (2015) Cristina Correia et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
- (2015) Allyson K. Palmer et al. DIABETES
- Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
- (2015) Jianhui Chang et al. NATURE MEDICINE
- Targeting senescent cells enhances adipogenesis and metabolic function in old age
- (2015) Ming Xu et al. eLife
- Cellular senescence and the senescent secretory phenotype in age-related chronic diseases
- (2014) Yi Zhu et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- Cellular senescence and the senescent secretory phenotype: therapeutic opportunities
- (2013) Tamara Tchkonia et al. JOURNAL OF CLINICAL INVESTIGATION
- BH3 Mimetics: Status of the Field and New Developments
- (2013) C. Billard MOLECULAR CANCER THERAPEUTICS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
- (2012) Thanh-Trang Vo et al. CELL
- Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence
- (2012) Graeme Hewitt et al. Nature Communications
- Ethanol promotes mammary tumor growth and angiogenesis: the involvement of chemoattractant factor MCP-1
- (2011) Siying Wang et al. BREAST CANCER RESEARCH AND TREATMENT
- Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases
- (2011) Andreas Strasser et al. EMBO JOURNAL
- Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
- (2011) Darren J. Baker et al. NATURE
- Fat tissue, aging, and cellular senescence
- (2010) Tamara Tchkonia et al. AGING CELL
- Aging, Depot Origin, and Preadipocyte Gene Expression
- (2010) Mark J. Cartwright et al. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
- Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
- (2010) S. K. Tahir et al. MOLECULAR CANCER THERAPEUTICS
- Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
- (2009) M. H. Kang et al. CLINICAL CANCER RESEARCH
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
- (2008) M Vogler et al. CELL DEATH AND DIFFERENTIATION
- Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein–protein interaction
- (2008) Michael D Wendt Expert Opinion on Drug Discovery
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started